Celcuity

Celcuity

Brian Sullivan, the firm's founding CEO, launched Celcuity in 2012 to address a persistent gap in precision oncology: genomic tests identify mutations but rarely reveal whether the associated cellular signaling networks are actually driving tumor growth. Celcuity's proprietary CELsignia platform measures dysregulated pathway activity directly from live tumor cells, providing a functional readout that genomic assays cannot offer. The technology was in-licensed from the H. Lee Moffitt Cancer Center and the University of South Florida. Celcuity operates across two distinct business lines. The first is a diagnostics service that partners with pharmaceutical companies to stratify patients in clinical trials — identifying those whose tumors show hyperactive PI3K, MAPK, or other signaling pathways and are therefore most likely to respond to pathway-targeted drugs. Named collaborators have included Novartis, Genentech, Puma Biotechnology, and other oncology-focused biopharma firms. The diagnostic revenue model is fee-for-service, tied to trial enrollment and sample volume. The second business line is internal drug development. Celcuity acquired the global rights to gedatolisib, an intravenously administered pan-PI3K/mTOR inhibitor, from Pfizer in 2021 (per the firm, 2021). The company has advanced gedatolisib into a Phase 3 registration trial — VIKTORIA-1 — evaluating the drug in combination with fulvestrant, with or without palbociclib, for HR+/HER2- advanced breast cancer. As of early 2024, Celcuity is a publicly traded clinical-stage company with a wholly owned precision-medicine subsidiary. The firm operates from a single headquarters in Minneapolis, Minnesota. The professional team is compact and research-intensive, with expertise spanning cell biology, oncology, and clinical trial operations. In February 2024, Celcuity announced that the first patient had been dosed in the VIKTORIA-1 Phase 3 clinical trial, a key operational milestone that transitions the firm from a diagnostics-centric model toward an integrated biopharmaceutical development organization (per the firm, February 2024). The company has not disclosed a separate family-office structure or philanthropic vehicle. Celcuity's structural distinction lies in its dual revenue engine: a diagnostic services business that generates near-term cash from pharma partnerships while a wholly owned therapeutic program — gedatolisib — creates longer-term upside tied to regulatory and clinical success. This architecture is unusual in precision oncology. Most diagnostic firms license out discoveries or remain pure-play service providers. Celcuity uses its diagnostic platform to inform its own drug-development decisions, effectively running a vertically integrated model where the same pathway-activity data that guides trial stratification for partners also validates internal therapeutic hypotheses.